ES2906630T3 - Inhibidor del complemento ornithodoros moubata para uso en el tratamiento de enfermedades mediadas por el complemento en pacientes con polimorfismo C5 - Google Patents

Inhibidor del complemento ornithodoros moubata para uso en el tratamiento de enfermedades mediadas por el complemento en pacientes con polimorfismo C5 Download PDF

Info

Publication number
ES2906630T3
ES2906630T3 ES15728491T ES15728491T ES2906630T3 ES 2906630 T3 ES2906630 T3 ES 2906630T3 ES 15728491 T ES15728491 T ES 15728491T ES 15728491 T ES15728491 T ES 15728491T ES 2906630 T3 ES2906630 T3 ES 2906630T3
Authority
ES
Spain
Prior art keywords
complement
protein
agent
subject
polymorphism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15728491T
Other languages
English (en)
Spanish (es)
Inventor
Wynne H Weston-Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volution Immuno Pharmaceuticals SA
Original Assignee
Volution Immuno Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volution Immuno Pharmaceuticals SA filed Critical Volution Immuno Pharmaceuticals SA
Application granted granted Critical
Publication of ES2906630T3 publication Critical patent/ES2906630T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES15728491T 2014-06-06 2015-06-08 Inhibidor del complemento ornithodoros moubata para uso en el tratamiento de enfermedades mediadas por el complemento en pacientes con polimorfismo C5 Active ES2906630T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1410116.6A GB201410116D0 (en) 2014-06-06 2014-06-06 Method of treatment
PCT/EP2015/062742 WO2015185760A1 (en) 2014-06-06 2015-06-08 Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism

Publications (1)

Publication Number Publication Date
ES2906630T3 true ES2906630T3 (es) 2022-04-19

Family

ID=51266841

Family Applications (2)

Application Number Title Priority Date Filing Date
ES15728491T Active ES2906630T3 (es) 2014-06-06 2015-06-08 Inhibidor del complemento ornithodoros moubata para uso en el tratamiento de enfermedades mediadas por el complemento en pacientes con polimorfismo C5
ES15807907T Active ES2906632T3 (es) 2014-06-06 2015-12-09 Inhibidor del complemento ornithodoros moubata para uso en el tratamiento de enfermedad aguda de injerto versus huésped

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15807907T Active ES2906632T3 (es) 2014-06-06 2015-12-09 Inhibidor del complemento ornithodoros moubata para uso en el tratamiento de enfermedad aguda de injerto versus huésped

Country Status (16)

Country Link
US (3) US11052129B2 (cg-RX-API-DMAC10.html)
EP (1) EP3151851B1 (cg-RX-API-DMAC10.html)
JP (2) JP7045133B2 (cg-RX-API-DMAC10.html)
KR (1) KR102439717B1 (cg-RX-API-DMAC10.html)
CN (1) CN106659767B (cg-RX-API-DMAC10.html)
AU (1) AU2015270396B2 (cg-RX-API-DMAC10.html)
BR (1) BR112016028446A2 (cg-RX-API-DMAC10.html)
CA (1) CA2951175A1 (cg-RX-API-DMAC10.html)
DK (2) DK3151851T3 (cg-RX-API-DMAC10.html)
ES (2) ES2906630T3 (cg-RX-API-DMAC10.html)
GB (1) GB201410116D0 (cg-RX-API-DMAC10.html)
IL (1) IL249237B (cg-RX-API-DMAC10.html)
MX (1) MX382757B (cg-RX-API-DMAC10.html)
PL (2) PL3151851T3 (cg-RX-API-DMAC10.html)
RU (1) RU2700932C2 (cg-RX-API-DMAC10.html)
WO (1) WO2015185760A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016198133A1 (en) * 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
GB201602802D0 (en) * 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
CN109328197A (zh) * 2016-06-07 2019-02-12 诺华股份有限公司 用于治疗具有补体c5多态性的患者的抗c5抗体
SE540754C2 (en) * 2016-11-30 2018-10-30 Ikea Supply Ag Molding of fiber blanks into three-dimensional fiber block
CN110831617A (zh) * 2017-04-21 2020-02-21 沃卢申伊缪诺制药公司 用于治疗瘢痕性眼部发炎性病症的Coversin
JP7209637B2 (ja) 2017-04-21 2023-01-20 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン
WO2019186084A1 (en) * 2018-03-26 2019-10-03 The University Of Liverpool Anti-complement histones
JP7629394B2 (ja) * 2018-09-10 2025-02-13 ヴォリューション イミュノ ファーマシューティカルズ エスエイ リウマチ性疾患の治療に使用するためのコバーシン
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054033A9 (en) * 1995-08-30 2005-03-10 Human Genome Sciences, Inc. Methods and compositions for treating and preventing infection using human interferon regulatory factor 3
GB0312619D0 (en) * 2003-06-02 2003-07-09 Evolutec Ltd Complement inhibitors
US7884188B2 (en) 2003-06-02 2011-02-08 Varleigh Immuno Pharmaceuticals (Vip) Ltd Complement inhibitors
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
EP2061501B1 (en) * 2006-09-08 2015-04-08 Volution Immuno Pharmaceuticals SA Method of treating respiratory disorders
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
GB0906779D0 (en) 2009-04-20 2009-06-03 Natural Environment Res Council Composition
CA2785612C (en) 2010-01-08 2019-09-10 Varleigh Immuno Pharmaceuticals (Vip) Ltd. Ev576 for use in the treatment of viral infections of the respiratory tract
TW201418707A (zh) * 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
JP7209637B2 (ja) 2017-04-21 2023-01-20 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン

Also Published As

Publication number Publication date
JP2017518316A (ja) 2017-07-06
MX382757B (es) 2025-03-13
CN106659767B (zh) 2022-08-30
EP3151851A1 (en) 2017-04-12
EP3151851B1 (en) 2021-12-01
KR102439717B1 (ko) 2022-09-02
DK3151851T3 (da) 2022-02-28
CN106659767A (zh) 2017-05-10
DK3302519T3 (da) 2022-02-28
NZ727053A (en) 2023-10-27
BR112016028446A2 (pt) 2017-10-24
RU2016151179A (ru) 2018-07-16
IL249237A0 (en) 2017-02-28
ES2906632T3 (es) 2022-04-19
AU2015270396A1 (en) 2016-12-15
KR20170016893A (ko) 2017-02-14
US20170196936A1 (en) 2017-07-13
AU2015270396B2 (en) 2020-07-16
US20210283221A1 (en) 2021-09-16
RU2700932C2 (ru) 2019-09-24
CA2951175A1 (en) 2015-12-10
WO2015185760A1 (en) 2015-12-10
MX2016016139A (es) 2017-07-28
RU2016151179A3 (cg-RX-API-DMAC10.html) 2019-01-22
GB201410116D0 (en) 2014-07-23
JP2018516944A (ja) 2018-06-28
JP6767396B2 (ja) 2020-10-14
JP7045133B2 (ja) 2022-03-31
US11052129B2 (en) 2021-07-06
PL3302519T3 (pl) 2022-04-25
IL249237B (en) 2020-09-30
US20180193417A1 (en) 2018-07-12
PL3151851T3 (pl) 2022-04-04

Similar Documents

Publication Publication Date Title
US20210283221A1 (en) Ornithodoros Moubata Complement Inhibitor for Use in the treatment of Complement-Mediated Diseases in Patients with C5 Polymorphism
US20240009270A1 (en) Coversin for the treatment of autoimmune blistering diseases
JP5784078B2 (ja) 呼吸器疾患の治療方法
EP3302519B1 (en) Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
US20250195612A1 (en) Coversin for use in the treatment of rheumatic diseases
US20180335433A1 (en) Compositions targeting pkc-theta and uses and methods of treating pkc-theta pathologies, adverse immune responses and diseases
CN117794572A (zh) 用于治疗感染后自身免疫性糖尿病的方法
AU2019468121A1 (en) Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)
NZ727053B2 (en) Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism